All GLG News Analyses Filed Under: Legal Issues

The debate of uses of genetic information for insurance purposes unfortunately masks the underlying problem:  namely, the failure or inability of Congress to address the failure of the US health care system to allocate risks and costs based on rational policy choices, rather than based upon the...

In discounting  prospects for "winning in court" in litigation arising from losses in the mortgage market, the NYT unfortunately ignores a growing, and perhaps ultimately the primary, form of non-class action private securities litigation--litigation under state securities laws, which generally...

No recovery for investors from CMO/CDO's Financial Market regulation to increase Arbitration volume to increase relatively more than lawsuits

Gene research may be a double edged sword!Will HIPPA apply to genetic testing!

Filing the lawsuit for home loan problems is easy, winning will be the real problem!The Supreme Court seems to be raising the bar on the burden of proof!

It should be noted that the conflict of interest in most of these cases is very significant. However, disability insurers, like MetLife, use the limited scope of discovery many federal courts have adopted under ERISA to hide the conflict and keep any real evidnence of the financial conflict out...

The burden of proof may shift to insurers when insureds submit claims.Will the review of insurance claims be subjective or objective?

As much as everyone yearns for closure, the reality of the QCOM/NOK fight is that we still have years on the clock.

Tessera continues to focus public attention on its arbitration with Amkor.  But the real action these next few months will not come from that corner.  Instead, the real action is going to be the looming final decision about TSRA's '419 patent.

Rambus has scored two big legal victories over the last few weeks.  Now, all eyes turn to the summer, where three more big legal events could determine the firm's fate.